OBJECTIVE: Circulating immune complexes (IC) containing modified forms of LDL (mLDL) are strongly pro-inflammatory and strong predictors of cardiovascular disease (CVD) progression in type 1 diabetes. The present study was undertaken to determine whether the levels of oxidized LDL (oxLDL), malondialdehyde-LDL (MDA-LDL) and advanced glycation end products-LDL (AGE-LDL) in IC predict incident CVD events in type 2 diabetes (VADT cohort). METHODS AND RESULTS:Levels of mLDL in IC were measured in 907 patients of the VADT cohort, a median of two years after entry into the study. Participants were followed for an average of 3.7 years for vascular outcomes. Hazard ratios (HRs) for CV endpoints in relation to mLDL-IC quartiles were calculated by Cox proportional hazard models. The primary composite CVD endpoint included documented myocardial infarction (MI); stroke; death from CVD; congestive heart failure; cardiac, cerebrovascular, or peripheral VD surgical intervention; inoperable CVD; and amputation for ischemic gangrene. During follow-up, 4.7% and 16.8% of participants had an MI or a composite endpoint, respectively. After adjustments by conventional risk factors, individuals in the highest quartile of MDA-LDL-IC were at higher risk of MI [HR = 2.44 (95% CI: 1.03, 5.77)] and composite endpoint [HR = 1.71 (95% CI: 1.04, 2.80)], relative to individuals in the lowest quartile. Similar comparisons for oxLDL and AGE-LDL levels yielded HR values of 1.08 and 1.31 for MI and 0.91 and 1.34 for composite endpoint. CONCLUSIONS: Our study indicates that high levels of MDA-LDL in isolated IC predict future MI and acute CV events in patients with type 2 diabetes. Published by Elsevier Ireland Ltd.
RCT Entities:
OBJECTIVE: Circulating immune complexes (IC) containing modified forms of LDL (mLDL) are strongly pro-inflammatory and strong predictors of cardiovascular disease (CVD) progression in type 1 diabetes. The present study was undertaken to determine whether the levels of oxidized LDL (oxLDL), malondialdehyde-LDL (MDA-LDL) and advanced glycation end products-LDL (AGE-LDL) in IC predict incident CVD events in type 2 diabetes (VADT cohort). METHODS AND RESULTS: Levels of mLDL in IC were measured in 907 patients of the VADT cohort, a median of two years after entry into the study. Participants were followed for an average of 3.7 years for vascular outcomes. Hazard ratios (HRs) for CV endpoints in relation to mLDL-IC quartiles were calculated by Cox proportional hazard models. The primary composite CVD endpoint included documented myocardial infarction (MI); stroke; death from CVD; congestive heart failure; cardiac, cerebrovascular, or peripheral VD surgical intervention; inoperable CVD; and amputation for ischemic gangrene. During follow-up, 4.7% and 16.8% of participants had an MI or a composite endpoint, respectively. After adjustments by conventional risk factors, individuals in the highest quartile of MDA-LDL-IC were at higher risk of MI [HR = 2.44 (95% CI: 1.03, 5.77)] and composite endpoint [HR = 1.71 (95% CI: 1.04, 2.80)], relative to individuals in the lowest quartile. Similar comparisons for oxLDL and AGE-LDL levels yielded HR values of 1.08 and 1.31 for MI and 0.91 and 1.34 for composite endpoint. CONCLUSIONS: Our study indicates that high levels of MDA-LDL in isolated IC predict future MI and acute CV events in patients with type 2 diabetes. Published by Elsevier Ireland Ltd.
Authors: Samar M Hammad; Waleed O Twal; Jeremy L Barth; Kent J Smith; Antonio F Saad; Gabriel Virella; W Scott Argraves; Maria F Lopes-Virella Journal: Atherosclerosis Date: 2008-05-28 Impact factor: 5.162
Authors: Maria F Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; John Lachin; David Nathan; G Virella Journal: Atherosclerosis Date: 2010-11-17 Impact factor: 5.162
Authors: Gabriel Virella; Suzanne R Thorpe; Nathan L Alderson; M Brooks Derrick; Charlyne Chassereau; J Matthew Rhett; Maria F Lopes-Virella Journal: J Lipid Res Date: 2004-07-16 Impact factor: 5.922
Authors: Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; John Lachin; David M Nathan; G Virella Journal: Diabetes Date: 2010-10-27 Impact factor: 9.461
Authors: Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2017-06-08
Authors: Maria F Lopes-Virella; Ionut Bebu; Kelly J Hunt; Gabriel Virella; Nathaniel L Baker; Barbara Braffett; Xiaoyu Gao; John M Lachin Journal: Diabetes Date: 2019-06-19 Impact factor: 9.461
Authors: Jeremy N Adams; Susan E Martelle; Laura M Raffield; Barry I Freedman; Carl D Langefeld; Fang-Chi Hsu; Joseph A Maldjian; Jeff D Williamson; Christina E Hugenschmidt; J Jeffery Carr; Amanda J Cox; Donald W Bowden Journal: J Diabetes Complications Date: 2015-11-30 Impact factor: 2.852
Authors: Kelly J Hunt; Miran A Jaffa; Sara M Garrett; Deirdre K Luttrell; Kenneth E Lipson; Maria F Lopes-Virella; Louis M Luttrell; Ayad A Jaffa Journal: Diabetes Care Date: 2018-01-30 Impact factor: 19.112